Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00658723 · ClinicalTrials.gov registry record · Phase 2
The Fibrin Patch Soft Tissue Study
A Phase 2 study, sponsored by Ethicon.
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
NCT00658723 is a Phase 2 study that has completed, run by Ethicon. The registered enrollment target is 141 participants.
The verdict
NCT00658723, a Phase 2 study, has completed, sponsored by Ethicon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
Study Summary
The effectiveness objective of this study is to evaluate whether Fibrin Patch is superior to SURGICEL™ as an adjunct to achieving hemostasis during surgical procedures involving soft tissue bleeding in abdominal, pelvic, retroperitoneal and (non-cardiac) thoracic surgery.
Interventions
- DRUG Fibrin Pad
- DEVICE SURGICEL™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00658723
The ClinicalTrials.gov registry entry for NCT00658723 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ethicon, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fibrin Pad is the first listed.
NCT00658723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00658723 about?
NCT00658723 is a clinical study titled "The Fibrin Patch Soft Tissue Study". The effectiveness objective of this study is to evaluate whether Fibrin Patch is superior to SURGICEL™ as an adjunct to achieving hemostasis during surgical procedures involving soft tissue bleeding in abdominal, pelvic, retroperitoneal and (non-cardiac) thoracic surgery.
What is the current status of trial NCT00658723?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2008-03. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00658723?
The interventions under investigation include: Fibrin Pad (DRUG), SURGICEL™ (DEVICE).
Who is sponsoring clinical trial NCT00658723?
This trial is sponsored by Ethicon, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.